Company profile
GERON CORP
NASDAQ:GERNBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| IMETELSTAT SODIUM | approved | — | 7 | approved |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (15)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04576156 | phase3 | active_not_recruiting | 2021-04-12 | 2028-06-30 | Geron Corporation | A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment |
| NCT00732056 | phase1 | completed | 2008-07-01 | 2011-09-01 | Geron Corporation | A Study of GRN163L With Paclitaxel and Bevacizumab to Treat Patients With Locally Recurrent Or Metastatic Breast Cancer |
| NCT05371964 | phase1 | active_not_recruiting | 2022-05-04 | 2027-02-01 | Geron Corporation | A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis |
| NCT01731951 | phase2 | completed | 2012-10-29 | 2018-05-24 | Geron Corporation | Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis |
| NCT01137968 | phase2 | completed | 2010-05-01 | 2013-09-01 | Geron Corporation | Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC) |
FDA applications (1)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 217779 | NDA | GERON CORP | ||||
Loading… | ||||||